Trial Profile
A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms STORM
- 02 Feb 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Results (n=46) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.